[go: up one dir, main page]

AR038834A1 - Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco - Google Patents

Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco

Info

Publication number
AR038834A1
AR038834A1 ARP030100404A AR038834A1 AR 038834 A1 AR038834 A1 AR 038834A1 AR P030100404 A ARP030100404 A AR P030100404A AR 038834 A1 AR038834 A1 AR 038834A1
Authority
AR
Argentina
Prior art keywords
formula
alkyl
group
phenyl
halo
Prior art date
Application number
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203196A external-priority patent/GB0203196D0/en
Priority claimed from GB0220999A external-priority patent/GB0220999D0/en
Priority claimed from GB0224453A external-priority patent/GB0224453D0/en
Priority claimed from GB0227139A external-priority patent/GB0227139D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR038834A1 publication Critical patent/AR038834A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Addiction (AREA)

Abstract

Derivados de nicotinamida y procedimientos para su preparación, intermedios utilizados en su preparación, composiciones que los contienen y los usos de dichos derivados. Los derivados de nicotinamida de acuerdo con la presente son útiles en numerosas enfermedades, trastornos y dolencias, en particular en enfermedades, trastornos y dolencias inflamatorios, alérgicos, respiratorios, así como en heridas. Reivindicación 1: Un compuesto de fórmula (1) en la cual R1 y R2 son cada uno un miembro independientemente seleccionado entre el grupo formado por átomo de H, halo, ciano, alquilo C1-4 y alcoxi C1-4, X es O, S, o NH, R3 es un miembro seleccionado entre los grupos formados por: (a) fenilo, naftilo, heteroarilo y cicloalquilo C3-8, cada uno opcionalmente sustituido con 1 a 3 sustituyentes cada uno seleccionado independientemente entre el grupo formado por halo, ciano, trifluorometilo, trifluoroetilo, trifluorometoxi, trifluoroetoxi, alquilo C1-4, alcoxi C1-4, tioalquilo C1-4, -C(=O)NH2, -C(=O)NH- (alquilo C1-4), hidroxi, -O-C-(=O))alquilo C1-4, -C(=O)-O-alquilo C1-4 e hidroxialquilo C1-4, cicloalquilo C3-8 y cicloalquiloxi C3-8, o (b) los grupos bicíclicos conforme a una de las siguientes estructuras (2), en la que el símbolo "*" indica el punto de unión de cada fórmula parcial a la porción restante de fórmula (1), Y es un miembro seleccionado entre el grupo formado por las fórmulas (3) en la que el símbolo "*" indica el punto de unión de cada fórmula (3) a las porciones -NH- restantes de fórmula (1) y "*" indica el punto de unión de cada fórmula parcial (3) a las porciones Z restantes de fórmula (1); y en que R5 es un miembro seleccionado entre los grupos formados por alquilo C1-4 y alquil C1-4-fenilo, en que dicho grupo fenilo está opcionalmente sustituido independientemente con 1 a 3 sustituyentes cada uno seleccionado entre el grupo formado por halo, ciano, alquilo C1-4, alcoxi C1-4, hidroxi, hidroxialquilo C1-4, ácido carboxílico, (-COOH), -C(=O)-O-alquilo C1-4, haloalquilo C1-4 y -C(O)NH2, Z es un miembro seleccionado entre el grupo formado por las fórmulas parciales (4) en la que el símbolo "*" indica el punto de unión de cada fórmula parcial (4) a las porciones y restantes de fórmula (1) y "*" indica el punto de unión de cada fórmula (4) a las porciones R4 restantes de fórmula (1), o alternativamente Y-Z juntos representa un grupo de fórmula (5), en la que el símbolo "*" indica el punto de unión de la fórmula parcial (5) a las porciones -NH- restantes de fórmula (1) y "*" indica el punto de unión de la fórmula (5) a las porciones -R4 restantes de fórmula (1), y R4 es un miembro seleccionado entre el grupo formado por: (a) fenilo, naftilo, heteroarilo y cicloalquilo C3-8, cada uno opcionalmente sustituido con 1 a 3 sustituyentes cada uno seleccionado independientemente entre el grupo formado por ácido carboxílico (-COOH), -C(=O)-O-alquilo C1-4, alquil C1-4-COOH, alquil C1-4-C(O)-O-alquiloC1-4, halo, ciano, -C(=O)NH2, alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, hidroxi e hidroxialquilo C1-4, o (b) alquilo C1-6 opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados entre el grupo formado por un grupo hidroxi, ácido carboxílico, -C(=O)-O-alquilo C1-4, fenilo, naftilo, heteroarilo o cicloalquilo C3-8, en que dichos grupos fenilo, naftilo, heteroarilo y cicloalquilo C3-8 están opcionalmente sustituidos con 1 a 3 sustituyentes cada uno seleccionado independientemente entre el grupo formado por ácido carboxílico (COOH), C(=O)Oalquilo C1-4, halo, ciano, C(=O)NH, alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, hidroxi e hidroxialquilo C1-4, o, si es apropiado, sus sales y /o isómeros, tautómeros, solvatos, polimorfos, variaciones isotópicas y metabolitos farmacéuticamente aceptables del mismo, con la condición que: 1) cuando: R1 se selecciona entre el grupo formado por átomo de H, halo y metilo R2 es un átomo de H, X es -O-, R3 es un fenilo sustituido con un tioalquilo C1-4 en la posición 3 o 4 de dicho fenilo y está también opcionalmente sustituido con un sustituyente seleccionado entre el grupo formado por halo, alquilo C1-3 y alcoxi C1-3, Y es una fórmula parcial (3) en la que el símbolo "*" indica el punto de unión de cada fórmula a las porciones -NH- restantes de fórmula (1) y "*" indica el punto de unión de cada fórmula parcial a las porciones Z restantes de fórmula (1), y en que R5 es un miembro seleccionado entre los grupos formados por alquilo C1-4 y alquil C1-4-fenilo, en que dicho grupo fenilo está opcionalmente sustituido con halo, alquilo C1-3, alcoxi C1-3 o hidroxi, y Z es un radical -C(=O)- entonces R4 no puede ser: a) un cicloalquilo C3-8 opcionalmente sustituido con alquilo C1-3, (b) un fenilo o un anillo heterocíclico de 5 o 6 miembros que incorpora 1 a 3 heteroátomo (s) seleccionado (s) independientemente entre N, O, y S, cuyo fenilo y anillo heterocíclico están cada uno opcionalmente sustituidos con hidroxi, halo, alquilo C1-3 o alcoxi C1-3, o (c) un alquilo C1-6 opcionalmente sustituido con un hidroxi, o con un fenilo o un anillo heterocíclico de 5 o 6 miembros que incorpora 1 a 3 heteroátomo (s) seleccionado (s) independientemente entre N, O, y S, cuyo fenilo y anillo heterocíclico está cada uno opcionalmente sustituido con hidroxi, halo, alquilo C1-3 o alcoxi C1-3, 2) y cuando: R1 se selecciona entre el grupo formado por un átomo de H, halo y metilo, R2 es un átomo de H, X es -O-, R3 es un fenilo sustituido con un tioalquilo C1-4 en la posición 3 o 4 de dicho fenilo y está también opcionalmente sustituido con 1 sustituyente seleccionado entre el grupo formado por halo, alquilo C1-3 y alcoxi C1-3, y Y-Z representa una fórmula parcial (5) en la que el símbolo "*" indica el punto de unión de la fórmula parcial (5) a las porciones -NH- restantes de fórmula (1) y "*" indica el punto de unión de la fórmula parcial (5) a las porciones R4 restantes de fórmula (1), entonces R4 no puede ser (a) un cicloalquilo C3-8 o (b) un alquilo C1-6 opcionalmente sustituido con un fenilo o un anillo heterocíclico de 5 o 6 miembros que incorpora 1 a 3 heteroátomo (s) seleccionados independientemente entre N, O, y S, cuyo fenilo y anillo heterocíclico están cada uno opcionalmente sustituidos con hidroxi, halo, alquilo C1-3 o alcoxi C1-3, 3) y cuando; R1 se selecciona entre el grupo formado por átomo de H, halo y metilo, R2 es un átomo de H, X es -O-, R3 es un fenilo sustituido con un tioalquilo C1-4 en la posición 3 o 4 de dicho fenilo y está también opcionalmente sustituido con 1 o 2 sustituyente (s) cada uno independientemente seleccionado entre el grupo formado por halo, alquilo C1-3 y alcoxi C1-3, y Y es una fórmula parcial (3) en la que el símbolo "*" indica el punto de unión de cada fórmula parcial a las porciones -NH- restantes de fórmula (1) y "*" indica el punto de unión de cada fórmula parcial a las porciones Z restantes de fórmula (1), y Z es un radical -C(O)- entonces R4 no puede ser alquilo C1-6 opcionalmente sustituido con un hidroxi, o con un anillo heterocíclico de 5 o 6 miembros que incorpora 1 a 3 heteroátomo (s) seleccionado (s) independientemente entre N, O y S. Reivindicación 5 Un procedimiento para la preparación de un compuesto de fórmula (1) como se describe en la reivindicación 1, en la que Z representa un grupo de fórmula parcial (4), o una sal o forma derivada farmacéuticamente aceptable del mismo, caracterizado porque comprende la etapa de hacer reaccionar un compuesto de fórmula (6) en la que R1, R2, X, R3, e Y son como se definen en la reivindicación 1, con el correspondiente derivado cloruro de R4-sulfonilo en que Z representa un grupo de fórmula parcial (4) o con el correspondiente derivado ácido R4-carboxílico en que Z representa un grupo de fórmula parcial (4), o con carbonildiimidazol en que Z representa un grupo de fórmula parcial (4).
ARP030100404 2002-02-11 2003-02-10 Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco AR038834A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0203196A GB0203196D0 (en) 2002-02-11 2002-02-11 Nicotinamide derivatives useful as pde4 inhibitors
GB0220999A GB0220999D0 (en) 2002-09-10 2002-09-10 Nicotinamide derivatives useful as pde4 inhibitors
GB0224453A GB0224453D0 (en) 2002-10-21 2002-10-21 Nicotinamide derivatives useful as PDE4 inhibitors
GB0227139A GB0227139D0 (en) 2002-11-20 2002-11-20 Nicotinamide derivatives useful as pde4 inhibitors

Publications (1)

Publication Number Publication Date
AR038834A1 true AR038834A1 (es) 2005-01-26

Family

ID=27739229

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100404 AR038834A1 (es) 2002-02-11 2003-02-10 Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco

Country Status (33)

Country Link
US (3) US6949573B2 (es)
EP (1) EP1476158B1 (es)
JP (1) JP4583761B2 (es)
KR (1) KR100698982B1 (es)
CN (1) CN1652782A (es)
AP (1) AP2004003100A0 (es)
AR (1) AR038834A1 (es)
AT (1) ATE378049T1 (es)
AU (1) AU2003245711A1 (es)
BR (1) BR0307564A (es)
CA (1) CA2475712C (es)
DE (1) DE60317466T2 (es)
EA (1) EA008939B1 (es)
EC (1) ECSP045228A (es)
ES (1) ES2292988T3 (es)
GE (1) GEP20074055B (es)
HN (1) HN2003000064A (es)
HR (1) HRP20040708A2 (es)
MA (1) MA27174A1 (es)
MX (1) MXPA04007737A (es)
MY (1) MY135856A (es)
NI (1) NI200300025A (es)
NO (1) NO20043793L (es)
NZ (1) NZ534197A (es)
OA (1) OA12768A (es)
PA (1) PA8566401A1 (es)
PE (1) PE20030868A1 (es)
PL (1) PL372756A1 (es)
RS (1) RS70104A (es)
TN (1) TNSN04151A1 (es)
TW (1) TW200305419A (es)
UY (1) UY27659A1 (es)
WO (1) WO2003068235A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
PL372756A1 (en) * 2002-02-11 2005-08-08 Pfizer Inc. Nicotinamide derivatives useful as pde4 inhibitors
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US20050186276A1 (en) * 2003-07-17 2005-08-25 Pfizer Inc Pharmaceutical formulations
GB0317516D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0317472D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US7132435B2 (en) 2003-07-25 2006-11-07 Pfizer Inc. Compounds
GB0317509D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0317484D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
GB0317471D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Novel compounds
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
TWI339578B (en) 2004-10-29 2011-04-01 Mitsubishi Tanabe Pharma Corp Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions
US7829585B2 (en) * 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2292209A3 (en) 2005-09-12 2011-05-04 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyramidine-sulfamide
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
RU2008122978A (ru) 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
SI2297106T1 (sl) * 2008-05-27 2014-09-30 Astrazeneca Ab Fenoksipiridinilamid derivati in njih uporaba pri zdravljenju PDE4 posredovanih bolezenskih stanj
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011087812A1 (en) * 2009-12-21 2011-07-21 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US10431825B2 (en) * 2013-08-08 2019-10-01 Nec Corporation Negative electrode for secondary battery, method for manufacturing same, and secondary battery using same
AU2019301628C1 (en) * 2018-07-09 2025-02-06 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
CN109674808A (zh) * 2019-01-30 2019-04-26 四川大学 β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途
CN114573476B (zh) * 2020-09-14 2024-06-11 广州药本君安医药科技股份有限公司 线性头尾二胺桥连化合物及在制备治疗糖代谢紊乱疾病药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EA003528B1 (ru) * 1997-04-04 2003-06-26 Пфайзер Продактс Инк. Производные никотинамида, их применение, фармацевтическая композиция, способ лечения и способ ингибирования изоферментов фдэ4 d
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9924092D0 (en) * 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
BR0107964A (pt) 2000-01-31 2002-10-29 Pfizer Prod Inc Derivados de nicotinamida benzofundida com heterociclica úteis como inibidores seletivos de isozimas pde4
GB0203193D0 (en) 2002-02-11 2002-03-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
PL372756A1 (en) * 2002-02-11 2005-08-08 Pfizer Inc. Nicotinamide derivatives useful as pde4 inhibitors
WO2003068233A1 (en) 2002-02-11 2003-08-21 Pfizer Limited Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
GB0317516D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors

Also Published As

Publication number Publication date
CN1652782A (zh) 2005-08-10
OA12768A (en) 2006-07-04
ATE378049T1 (de) 2007-11-15
NI200300025A (es) 2005-09-21
DE60317466T2 (de) 2008-03-06
GEP20074055B (en) 2007-03-12
PL372756A1 (en) 2005-08-08
US20040224975A1 (en) 2004-11-11
KR100698982B1 (ko) 2007-03-26
MXPA04007737A (es) 2004-10-15
EP1476158A1 (en) 2004-11-17
ECSP045228A (es) 2004-09-28
AU2003245711A1 (en) 2003-09-04
TW200305419A (en) 2003-11-01
JP4583761B2 (ja) 2010-11-17
WO2003068235A1 (en) 2003-08-21
NZ534197A (en) 2007-01-26
MA27174A1 (fr) 2005-01-03
DE60317466D1 (de) 2007-12-27
US6949573B2 (en) 2005-09-27
MY135856A (en) 2008-07-31
PA8566401A1 (es) 2003-11-12
ES2292988T3 (es) 2008-03-16
EA200400892A1 (ru) 2005-02-24
HRP20040708A2 (en) 2005-06-30
AP2004003100A0 (en) 2004-09-30
EA008939B1 (ru) 2007-10-26
JP2005522450A (ja) 2005-07-28
EP1476158B1 (en) 2007-11-14
KR20040079994A (ko) 2004-09-16
US7060717B2 (en) 2006-06-13
RS70104A (sr) 2007-02-05
US20030220366A1 (en) 2003-11-27
PE20030868A1 (es) 2003-10-21
US20060014780A1 (en) 2006-01-19
CA2475712A1 (en) 2003-08-21
BR0307564A (pt) 2004-12-21
CA2475712C (en) 2009-11-24
NO20043793L (no) 2004-10-21
TNSN04151A1 (fr) 2007-03-12
UY27659A1 (es) 2003-09-30
HN2003000064A (es) 2003-11-24

Similar Documents

Publication Publication Date Title
AR038834A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco
AR038835A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para tratar enfermedades, el compuesto activo, una composicion farmaceutica que incluye la combinacion y uso de esta para la fabricacion de un farmaco
AR038404A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye
AR012825A1 (es) Piridinas substituidas como inhibidores selectivos de ciclooxigenasa 2, una composicion farmaceutica que las contiene y su uso para la fabricacion de medicamentos
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
GT200400116A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
CA2628131A1 (en) Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AR097024A1 (es) Derivados sustituidos de quinazolin-4-ona
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
CY1108913T1 (el) Παραγωγα 4 (φαινυλ-πιπεραζινυλ-μεθυλ) βενζαμιδιου και η χρηση τους για τη θεραπευτικη αντιμετωπιση του πονου, του αγχους ή γαστρεντερικων διαταραχων
AR036659A1 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
CO5261634A1 (es) Derivados de nicotinamida benzocondensada-heterociclico utiles como inhibidores selectivos de las isozimas pde4
AR066043A1 (es) Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1)
AR067060A1 (es) Derivados de guanina policiclicos y sus metodos de uso
TW200607504A (en) Cinnamide compound
AR032361A1 (es) Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
EA200602058A1 (ru) Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas

Legal Events

Date Code Title Description
FB Suspension of granting procedure